Drug-induced prolongation of the QT interval.

By G. Curigliano, C. Cipolla, F. D. De Braud. New England Journal of Medicine, 2004

943 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

hERG K(+) channels: structure, function, and clinical significance. (2012, methodology): “As a consequence of this potentially fatal unwanted side effect, several noncardiac medications have been severely restricted in their use, or removed from the pharmaceutical market altogether (525).”
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, unknown): “Similar trends were seen in earlier trials of mexiletine(363) and disopyramide.(362) In patients”
Tuning hERG out: Antitarget QSAR Models for Drug Development (2014, unknown): “, astemizole, terfenadine [3], cisapride [4], sertindole [5], terolidine, droperidol, lidoflazine, and grepafloxacin [6].”
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. (2004, unknown): “Prostate gland volume, mL 41 (15-110) 37 (15-117)”